ES2410160T3 - Inhibidor recombinante de tipo Kunitz - Google Patents

Inhibidor recombinante de tipo Kunitz Download PDF

Info

Publication number
ES2410160T3
ES2410160T3 ES05782904T ES05782904T ES2410160T3 ES 2410160 T3 ES2410160 T3 ES 2410160T3 ES 05782904 T ES05782904 T ES 05782904T ES 05782904 T ES05782904 T ES 05782904T ES 2410160 T3 ES2410160 T3 ES 2410160T3
Authority
ES
Spain
Prior art keywords
treatment
tumor
cancer
cells
amblyomin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05782904T
Other languages
English (en)
Spanish (es)
Inventor
Ana Marisa Chudzinski-Tavassi
Durvanel Augusto Instituto Butantaninst. Butata Maria
Isabel De Fatima Correia Instituto Butantan Batista
Paulo Lee Instituto Butantan Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uni & Atilde O Qu & Iacute Mica Farmaceutica Nac S A
Uni O Qu Mica Farmac Utica Nacional S/a
Fundacao de Amparo a Pesquisa do Estado de Sao Paulo FAPESP
Original Assignee
Uni & Atilde O Qu & Iacute Mica Farmaceutica Nac S A
Uni O Qu Mica Farmac Utica Nacional S/a
Fundacao de Amparo a Pesquisa do Estado de Sao Paulo FAPESP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni & Atilde O Qu & Iacute Mica Farmaceutica Nac S A, Uni O Qu Mica Farmac Utica Nacional S/a, Fundacao de Amparo a Pesquisa do Estado de Sao Paulo FAPESP filed Critical Uni & Atilde O Qu & Iacute Mica Farmaceutica Nac S A
Application granted granted Critical
Publication of ES2410160T3 publication Critical patent/ES2410160T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
ES05782904T 2004-09-15 2005-09-15 Inhibidor recombinante de tipo Kunitz Expired - Lifetime ES2410160T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRPI0406057 2004-09-15
BRPI0406057-1A BRPI0406057B1 (pt) 2004-09-15 2004-09-15 Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante
PCT/BR2005/000185 WO2006029492A1 (en) 2004-09-15 2005-09-15 Kunitz-type recombinant inhibitor.

Publications (1)

Publication Number Publication Date
ES2410160T3 true ES2410160T3 (es) 2013-07-01

Family

ID=36273230

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05782904T Expired - Lifetime ES2410160T3 (es) 2004-09-15 2005-09-15 Inhibidor recombinante de tipo Kunitz

Country Status (10)

Country Link
US (1) US8440795B2 (enExample)
EP (1) EP1799707B1 (enExample)
JP (1) JP4980220B2 (enExample)
CN (1) CN101142232B (enExample)
AU (1) AU2005284615B2 (enExample)
BR (1) BRPI0406057B1 (enExample)
CA (2) CA2581001C (enExample)
DK (1) DK1799707T3 (enExample)
ES (1) ES2410160T3 (enExample)
WO (1) WO2006029492A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109976A1 (en) * 2007-03-14 2008-09-18 União Química Farmacêutica Nacional S/A Kunitz-type recombinant inhibitor
BRPI0406057B1 (pt) 2004-09-15 2021-10-26 União Química Farmacêutica Nacional S/A Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante
NZ593815A (en) 2008-12-19 2013-05-31 Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
US8772238B2 (en) 2009-03-18 2014-07-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
BR102018074043A2 (pt) * 2018-11-22 2020-06-02 Inst Butantan composto para a modulação de vias de rlr, tlr, oas e/ou oncostatina m, uso do mesmo para a preparação de um medicamento, composição e método para modulação das ditas vias
BR102018074037A2 (pt) * 2018-11-22 2021-05-11 Inst Butantan composto para direcionar entidades moleculares para o domínio intracelular de células neoplásicas, ingrediente farmacêutico ativo compreendendo o referido composto, composição farmacêutica, método para o diagnóstico, prognóstico e/ou tratamento de câncer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3006207C2 (de) * 1980-02-15 1982-10-21 Siemens AG, 1000 Berlin und 8000 München Elektrische Maschine mit einem Ständerblechpaket aus kornorientierten Blechen
DE3819078A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Amblyommin, ein neuer wirkstoff fuer die antikoagulationstherapie
BRPI0406057B1 (pt) 2004-09-15 2021-10-26 União Química Farmacêutica Nacional S/A Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante

Also Published As

Publication number Publication date
BRPI0406057B1 (pt) 2021-10-26
CA2581001C (en) 2011-05-03
US20090042786A1 (en) 2009-02-12
WO2006029492A1 (en) 2006-03-23
DK1799707T3 (da) 2013-05-21
CN101142232A (zh) 2008-03-12
BRPI0406057A (pt) 2006-05-02
JP2008512992A (ja) 2008-05-01
AU2005284615A1 (en) 2006-03-23
JP4980220B2 (ja) 2012-07-18
US8440795B2 (en) 2013-05-14
CA2680759A1 (en) 2008-09-18
AU2005284615B2 (en) 2011-03-31
EP1799707A1 (en) 2007-06-27
CA2581001A1 (en) 2006-03-23
EP1799707B1 (en) 2013-03-27
CN101142232B (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
Jia et al. Function of disintegrin-like/cysteine-rich domains of atrolysin A: inhibition of platelet aggregation by recombinant protein and peptide antagonists
Huber-Lang et al. Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions
EP2698378B1 (en) Anticoagulant polypeptide and applications thereof
AU2010299631A1 (en) Polypeptides and uses thereof
JPH04504952A (ja) セルピン抵抗性キモトリプシン　スーパーフアミリー　プロテアーゼ、特にＰＡＩ―１抵抗性ｔ―ＰＡ、相補的阻害剤変異株；組成；遺伝子；発現
US8440795B2 (en) Kunitz-type recombinant inhibitor
Brito et al. The Kallikrein Inhibitor from Bauhinia bauhinioides (BbKI) shows antithrombotic properties in venous and arterial thrombosis models
Zhang et al. The tissue factor pathway inhibitor 1 of Sciaenops ocellatus possesses antimicrobial activity and is involved in the immune response against bacterial infection
KR101296367B1 (ko) 프로테아제 억제 단백질 및 그 이용
WO2007101602A9 (en) Chimeric kunitz domains and their use
EP2134843A1 (en) Kunitz-type recombinant inhibitor
Monti Von Willebrand factor, ADAMTS13 and neutrophil extracellular traps: allies in cancer-associated thrombosis and tumor progression
Palumbo et al. Genetic analysis of hemostatic factors and cancer
CN106928334A (zh) 约安巨马陆抗血栓肽Joannsin及其应用
WO2006112451A1 (ja) プロテインｃインヒビターを含有する抗癌剤
Zhang et al. Identification and analysis of the tissue factor pathway inhibitor 2 of Sciaenops ocellatus
Johnson et al. Plasminogen activator inhibitor type-2 (PAI-2)/SerpinB2: a unique multifunctional serpin
TW200846356A (en) Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
ES2400853T3 (es) Agente para mejorar la esperanza de vida en el tratamiento de una neoplasia
Makarova et al. Duodenase activates rat peritoneal mast cells via protease-activated receptors of type 1
Knight The role of PAR-1, PAR-2 and Tissue factor in the development of hepatic fibrosis
Woo et al. MOLECULAR STRUCTURE OF PLASMA PROTEASE INHIBITOR GENES IN MAN¹
BRPI0704854B1 (pt) uso de inibidores da agregação plaquetária e da coagulação isolados de bauhinia sp.
WO2007112531A1 (en) Use of protease inhibitors from bauhinia bauhinioides and/or enterolobium contortisiliquum
Mafra MASP2 and MBL2 gene polymorphisms in a Brazilian population